ICON Public Limited Company (ICLR) Reaches $124.82 52-Week High; Qs Investors Raised Its Eqt (EQT) Holding

May 11, 2018 - By Peter Erickson

ICON Public Limited Company (NASDAQ:ICLR) Logo

The stock of ICON Public Limited Company (NASDAQ:ICLR) hit a new 52-week high and has $136.05 target or 9.00% above today’s $124.82 share price. The 5 months bullish chart indicates low risk for the $6.75 billion company. The 1-year high was reported on May, 11 by Barchart.com. If the $136.05 price target is reached, the company will be worth $607.50M more. The stock increased 0.81% or $1 during the last trading session, reaching $124.82. About 26,473 shares traded. ICON Public Limited Company (NASDAQ:ICLR) has risen 52.69% since May 11, 2017 and is uptrending. It has outperformed by 41.14% the S&P500.

Qs Investors Llc increased Eqt Corp (EQT) stake by 27.59% reported in 2017Q4 SEC filing. Qs Investors Llc acquired 5,777 shares as Eqt Corp (EQT)’s stock declined 13.36%. The Qs Investors Llc holds 26,714 shares with $1.52M value, up from 20,937 last quarter. Eqt Corp now has $13.61B valuation. The stock decreased 0.62% or $0.32 during the last trading session, reaching $51.33. About 633,140 shares traded. EQT Corporation (NYSE:EQT) has declined 19.22% since May 11, 2017 and is downtrending. It has underperformed by 30.77% the S&P500.

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. The company has market cap of $6.75 billion. The firm specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It has a 24.33 P/E ratio. The Company’s clinical development services comprise product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services.

Among 12 analysts covering Icon plc (NASDAQ:ICLR), 7 have Buy rating, 1 Sell and 4 Hold. Therefore 58% are positive. Icon plc has $145.0 highest and $77 lowest target. $120.55’s average target is -3.42% below currents $124.82 stock price. Icon plc had 40 analyst reports since July 29, 2015 according to SRatingsIntel. The company was maintained on Friday, October 27 by Barclays Capital. The firm has “Hold” rating by SunTrust given on Friday, December 16. The firm has “Hold” rating by Jefferies given on Friday, June 3. On Monday, October 16 the stock rating was maintained by KeyBanc Capital Markets with “Buy”. The rating was upgraded by Goldman Sachs on Friday, December 16 to “Buy”. The rating was downgraded by Evercore on Tuesday, April 3 to “In-Line”. The firm has “Buy” rating given on Monday, October 30 by SunTrust. The firm has “Buy” rating by Robert W. Baird given on Thursday, February 15. The firm earned “Buy” rating on Monday, January 22 by SunTrust. Mizuho maintained it with “Hold” rating and $109.0 target in Wednesday, January 24 report.

More notable recent ICON Public Limited Company (NASDAQ:ICLR) news were published by: Seekingalpha.com which released: “ICON (ICLR) Q1 2018 Results – Earnings Call Transcript” on May 03, 2018, also Businesswire.com with their article: “ICON Sponsors Industry-Wide Clinical Trials Survey to Support Transforming Trials Initiative” published on May 09, 2018, Streetinsider.com published: “ICON plc (ICLR) Tops Q1 EPS by 2c, Updates Guidance” on May 03, 2018. More interesting news about ICON Public Limited Company (NASDAQ:ICLR) were released by: Globenewswire.com and their article: “Detailed Research: Economic Perspectives on ICON, Melco Resorts & Entertainment, Kornit Digital, MercadoLibre …” published on April 13, 2018 as well as Seekingalpha.com‘s news article titled: “Icon PLC Enjoying Wall Street Bonanza And FDA Tailwind” with publication date: May 07, 2018.

Since January 1, 2018, it had 4 insider buys, and 0 insider sales for $88,104 activity. Cary A. Bray Jr. bought $26,511 worth of EQT Corporation (NYSE:EQT) on Monday, April 2. Another trade for 447 shares valued at $21,237 was made by Szydlowski Norman J on Monday, April 2.

Among 21 analysts covering EQT Corporation (NYSE:EQT), 14 have Buy rating, 0 Sell and 7 Hold. Therefore 67% are positive. EQT Corporation had 86 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of EQT Corporation (NYSE:EQT) has “Hold” rating given on Thursday, August 31 by RBC Capital Markets. The stock has “Buy” rating by Cowen & Co on Tuesday, September 12. As per Tuesday, September 26, the company rating was upgraded by Seaport Global. As per Wednesday, October 18, the company rating was maintained by Morgan Stanley. The firm earned “Sector Outperform” rating on Friday, July 14 by Howard Weil. The firm has “Hold” rating given on Monday, June 19 by Jefferies. The rating was maintained by RBC Capital Markets on Wednesday, December 20 with “Hold”. The company was maintained on Thursday, December 14 by Morgan Stanley. The stock of EQT Corporation (NYSE:EQT) has “Hold” rating given on Friday, December 8 by Suntrust Robinson. As per Monday, October 26, the company rating was upgraded by Morgan Stanley.

More recent EQT Corporation (NYSE:EQT) news were published by: Globenewswire.com which released: “Consolidated Research: 2018 Summary Expectations for EQT, NiSource, Vulcan Materials, General Growth Properties …” on May 10, 2018. Also Bizjournals.com published the news titled: “EQT Midstream acquiring midstream assets worth more than $1.5B” on April 26, 2018. Bizjournals.com‘s news article titled: “Here’s what EQT paid its top execs in 2017” with publication date: May 01, 2018 was also an interesting one.

EQT Corporation (NYSE:EQT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News